Search
Get Involved

60th Anniversary Annual Awards

Date:
September 30, 2013
Time:
07:00 PM
Location:
Cipriani 42nd, New York, NY

The Cancer Research Institute held its 27th Annual Awards Dinner on Monday, September 30, 2013, at Cipriani 42nd. At this year's event, which celebrated the Institute's 60th anniversary, CRI presented the Oliver R. Grace Award for Distinguished Service in Advancing Cancer Research to Sean Parker for his work with Stand Up to Cancer and outstanding dedication to cancer immunotherapy through funding support of the SU2C-CRI Cancer Immunology Translational Research Dream Team. The second recipient of the award is Dr. Bahija Jallal, executive vice president of AstraZeneca and head of MedImmune, the global biologics research and development arm of AstraZeneca. Dr. Jallal is being honored for her work as part of the groundbreaking collaboration between MedImmune, CRI, and Ludwig Cancer Research to bring three promising immunotherapies into clinical trials.

CRI also bestowed the William B. Coley Award for Distinguished Research in Basic and Tumor Immunology to Dr. Michael Karin of the University of California, San Diego, for his groundbreaking work on the role of chronic inflammation in the development of tumors and his work demonstrating how external stimuli can control the activity of pathways and transcription factors that are responsible for regulating innate immunity and inflammation.

And CRI awarded the Frederick W. Alt Award for New Discoveries in Immunology to Dr. Jill O’Donnell-Tormey, CEO and director of scientific affairs at the Cancer Research Institute, for her role as a driving force in forging collaborative research required and in building the necessary infrastructure to facilitate translation of discoveries in the field to the clinic.

To learn more, read the news release here.

 

Photo Gallery

This year, CRI will give the Oliver R. Grace Award for Distinguished Service in Advancing Cancer Research to Sean Parker for his work with Stand Up to Cancer and outstanding dedication to cancer immunotherapy through funding support of the SU2C-CRI Cancer Immunology Translational Research Dream Team. The second recipient of the award is Dr. Bahija Jallal, executive vice president of AstraZeneca and head of MedImmune, the global biologics research and development arm of AstraZeneca. Dr. Jallal is being honored for her work as part of the groundbreaking collaboration between MedImmune, CRI, and the Ludwig Institute for Cancer Research to bring three promising immunotherapies into clinical trials. - See more at: http://www.cancerresearch.org/news/2013/august/cancer-research-institute-celebrating-60th-anniversary-at-27th-annual-awards-dinner#sthash.RdNFbmUJ.dpuf
presenting serial tech entrepreneur and philanthropist Sean Parker and MedImmune biotech head Dr. Bahija Jallal with its highest honor for people exceptionally dedicated to advancing cancer research. - See more at: http://www.cancerresearch.org/news/2013/august/cancer-research-institute-celebrating-60th-anniversary-at-27th-annual-awards-dinner#sthash.RdNFbmUJ.dpuf

Photos courtesy of Clint Spaulding/PatrickMcMullan.com

 

Video Playlist